Product Information
FENOFIBRATE 40 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $5.5354 per EA under NDC 00378439077. Its NADAC has been published 211 times since Jun 22, 2022.
FDA first approved this application on Jun 23, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the fenofibrate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378439077
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA204475FDA Approved
6/23/2016
TE Code
AB
On Market Since
6/23/2016
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 40 MG TABLET has been published 211 times since Jun 22, 2022, and over the history we have for it it has declined 15.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.5354 per EA |
|---|---|
| All-time high | $6.5784 (Apr 12, 2023) |
| All-time low | $5.1212 (Aug 21, 2024) |
| 52-week high | $6.4804 |
| 52-week low | $5.5354 |
| Median price | $5.9800 |
| Average price | $6.1005 |
| Largest weekly change | -9.3% (Apr 19, 2023) |
| Weeks tracked | 211 |
| Tracking since | Jun 22, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the fenofibrate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 40 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $5.5354 per EA (NDC 00378439077), effective Sep 30, 2026.
How has the price of FENOFIBRATE 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 40 MG TABLET has declined 15.9%. It has been tracked across 211 weekly CMS publications since Jun 22, 2022.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 40 MG TABLET?
Since Jun 22, 2022, the NADAC for FENOFIBRATE 40 MG TABLET has ranged from a low of $5.1212 (Aug 21, 2024) to a high of $6.5784 (Apr 12, 2023), with a median of $5.9800 per EA.
Are there cheaper alternatives to FENOFIBRATE 40 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of FENOFIBRATE 40 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FENOFIBRATE 40 MG TABLET?
FENOFIBRATE 40 MG TABLET (NDC 00378439077) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.